Astana Biomed Group, an authorized Abcam distributor in Central Asia

Human SIPA1L1 knockout HEK-293T cell lysate (ab263347)

Overview

  • Product name

    Human SIPA1L1 knockout HEK-293T cell lysate

  • Product overview


    Knockout cell lysate achieved by CRISPR/Cas9.

  • Parental Cell Line

    HEK293T

  • Organism

    Human

  • Mutation description

    Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.

  • Passage number

  • Knockout validation

    Sanger Sequencing

  • Reconstitution notes

    To use as WB control, resuspend the lyophilizate in 50 µL of LDS* Sample Buffer to have a final concentration of 2 mg/ml. For reducing conditions, we recommend a final concentration of 0.1 M DTT.

    *Usage of SDS sample buffer is not recommended with these lyophilized lysates.

  • Notes

    Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version - found here. Please refer to our lysis protocol for further details on how our lysates are prepared.

    User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

    Access thousands of knockout cell lysates, generated from commonly used cancer cell lines.
    See here for more information on knockout cell lysates.

    Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
    It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

    This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Properties

Target

  • Relevance

    SIPA1L1 (Signal-induced proliferation associated-like protein 1) is a member of the SIPA1 family of RapGAPs. SIPA1L1 was initially identified as a binding partner and degradation target of the E6 oncoprotein of high-risk papillomaviruses. Recently, it was discovered that Casein kinase I epsilon (CKIe), a Wnt-regulated kinase that regulates Wnt/b-catenin signaling, also can bind to the carboxy-terminus of SIPA1L1. CKIe phosphorylates SIPA1L1, thereby reducing its stability and alleviating its inhibition of Rap1, a protein required for Wnt8/CKIe-mediated gastrulation during embryogenesis, suggesting SIPA1L1 plays important roles in embryo development as well as control of cell proliferation.

  • Cellular localization

    Intracellular

  • Alternative names

    • DKFZp686G1344
    • E6 targeted protein 1
    • E6TP1
    • H_DJ1140G11.1
    • High risk human papilloma viruses E6 oncoproteins targeted protein 1
    • KIAA0440
    • Signal induced proliferation associated 1 like 1
    • Signal induced proliferation associated 1 like protein 1
    • SIPA1 like protein 1
    • WUGSC:H_DJ1140G11.1
    see all

Properties

Images

  • Sanger Sequencing - Human SIPA1L1 knockout HEK293T cell lysate (ab263347)
    Sanger Sequencing - Human SIPA1L1 knockout HEK293T cell lysate (ab263347)
    Homozygous: 1 bp insertion in exon4

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up